This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Jarboe, K. S. Search for Related Content Social Bookmarking                         What's this?

Considering the Impact on Overall Patient Health When Choosing Antipsychotic Therapy

Comprehensive Neuroscience, Inc., Atlanta, GA; e-mail: kjarboe@ cnsmail.com

Schizophrenia is a chronic and debilitating illness characterized by behaviors that markedly impair social and occupational functioning. Atypical antipsychotic medications have greatly improved outcomes for patients with these psychiatric disorders. Unfortunately, many patients do not respond adequately to therapy because of treatment-limiting adverse events, (AEs) which also limit therapeutic adherence. It is now widely accepted that the "real-world" clinical effectiveness of an atypical antipsychotic depends on its safety and tolerability as much as its efficacy. A number of clinical studies have shown that certain atypical antipsychotics are associated with unwanted sedation and a significant risk of weight gain, diabetes, and dyslipidemia. The risk of hyperprolactinemia is also significantly elevated with some atypical antipsychotics. To minimize the risk of adversely impacting overall patient health, each patient's metabolic and cardiovascular risk profile, as well as the potential impact of sedation on his or her quality of life, should be evaluated before beginning therapy and regularly thereafter. J Am Psychiatr Nurses Assoc, 2007; 13(S5), S23-S28. DOI: 10.1177/1078390307299810

Key Words: schizophrenia • antipsychotic drugs • adverse effects

Journal of the American Psychiatric Nurses Association, Vol. 13, No. 5 suppl, S23-S28 (2007)
DOI: 10.1177/1078390307299810


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. Phillips McEnany Psychopharmacologic Strategies and Associated Challenges in the Long-Term Treatment of Schizophrenia Journal of the American Psychiatric Nurses Association, November 1, 2007; 13(5_suppl): S6 - S15. [Abstract] [PDF]